KRAS and colorectal carcinoma: In CRC patients with WT KRAS, ~15% have BRAF V600E mutations4–7; therefore, BRAF V600E mutations could account for an additional 15% of patients who are KRAS WT but are non-responsive to anti-EGFR monoclonal antibodies4–7.